ASCO Quality Rapid Reaction

John Elliott from Carevive attended the ASCO Quality Conference in Chicago, where he had the opportunity to connect with partners and thought leaders in the field. The conference centered around quality improvement and its impact on patients, processes, and outcomes. John was joined by Dr. Glasnick, Carevive’s Chief Scientific Officer, and together they shared their insights from the event, particularly regarding electronic patient-reported outcomes (EPROs) and research.

Key Takeaways:
EPROs emerged as a prominent topic at ASCO Quality, with an emphasis on their implementation and integration into clinical care delivery. Dr. Glasnick highlighted the importance of utilizing data in real-time to provide clinicians with actionable insights, which Carevive excels at through its people-process-technology partnership. The discussions also delved into health equity, including considerations of differential access and tech literacy in implementing ePROs and related questionnaires. Financial toxicity was another significant aspect addressed, focusing on the challenges of selecting validated questionnaires, integrating them effectively, and leveraging the generated data for meaningful research.

Recent Episodes

In this episode of Inside Restoration & Recovery, host Martha Lewis welcomes Jason McClaren, Director of Facilities Operations at Reunion Rehabilitation Hospitals, to discuss the critical advantage of partnering with a restoration team experienced in healthcare. A former firefighter and military veteran, Jason has spent the last decade managing safety, risk, and emergency preparedness…

In this impactful episode of the ConCensis podcast, host Yasmeen Hassan sits down with Robby Miller, Sterile Processing Manager at St. Joseph’s Hospital Medical Center, to explore how artificial intelligence is revolutionizing the field of sterile processing. With nearly 30 years of experience in healthcare, Miller shares his journey from EMT to SPD leader, offering…

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…